Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 May;58(5):633-641.
doi: 10.1007/s00592-020-01661-y. Epub 2021 Jan 23.

The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF)

Paul Sandhu #  1 , Jann P Ong #  2 , Vinay Garg  2 , Mustafa Altaha  2 , Olubenga Bello  2 , Sewa R Singal  3   4 , Subodh Verma  5   6   7   8 , Andrew T Yan  9   10 , Kim A Connelly  11   12   13
Affiliations
Clinical Trial

The effects of saxagliptin on cardiac structure and function using cardiac MRI (SCARF)

Paul Sandhu et al. Acta Diabetol. 2021 May.

Abstract

Purpose: A recent large cardiovascular outcome trial in patients with type 2 diabetes (T2DM) demonstrated excess heart failure hospitalization with saxagliptin. We sought to evaluate the impact of saxagliptin on cardiac structure and function using cardiac magnetic resonance imaging (CMR) in patients with T2DM without pre-existing heart failure.

Methods: In this prospective study, patients with T2DM without heart failure were prescribed saxagliptin as part of routine guideline-directed management. Clinical assessment, CMR imaging and biomarkers were assessed in a blinded fashion and compared following 6 months of continued treatment. The primary outcome was the change in left ventricular (LV) ejection fraction (LVEF) after 6 months of therapy. Key secondary outcomes included changes in LV and right ventricular (RV) end-diastolic volume, ventricular mass, LV global strain and cardiac biomarkers [N terminal pro B-type natriuretic peptide (NT-proBNP) and high sensitivity C-reactive protein (hsCRP)] over 6 months.

Results: The cohort (n = 16) had a mean age of 59.9 years with 69% being male. The mean hemoglobin A1c (HbA1c) was 8.3%. Mean baseline LVEF was 57% ± 3.4, with no significant change over 6 months (- 0.2%, 95% CI - 2.5, 2.1, p = 0.86). Detailed CMR analyses that included LV/RV volumes, LV mass, and feature tracking-derived strain showed no significant change (all p > 0.50). NT-proBNP and hsCRP levels did not significantly change (p > 0.20).

Conclusions: In this cohort of stable ambulatory patients with T2DM without heart failure, saxagliptin treatment was not associated with adverse ventricular remodeling over 6 months as assessed using CMR and biomarkers.

Keywords: Cardiac MRI; Diabetes; Heart failure; Remodeling; Saxagliptin.

PubMed Disclaimer

References

    1. MacDonald MR, Petrie MC, Hawkins NM et al (2008) Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 29(10):1224–1240 - DOI
    1. MacDonald MR, Petrie MC, Varyani F et al (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure—an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29(11):1377–1385 - DOI
    1. Dauriz M, Targher G, Laroche C et al (2017) Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 40(5):671–678 - DOI
    1. Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326 - DOI
    1. Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373(3):232–242 - DOI

Publication types

MeSH terms

LinkOut - more resources